Systemic Therapy After Curative Local Treatment for Isolated Locoregional Recurrence in Triple-Negative Breast Cancer: Evidence Gaps and a Practical Clinical Framework TNBC LRR after curative local treatment
Abstract
N/A
Full text article
References
Wapnir IL, Price KN, Anderson SJ, et al. Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. J Clin Oncol. Apr 10 2018;36(11):1073-1079. doi:10.1200/JCO.2017.76.5719. DOI: https://doi.org/10.1200/JCO.2017.76.5719
Ferrari P, Scatena C, Ghilli M, Bargagna I, Lorenzini G, Nicolini A. Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC. Int J Mol Sci. Jan 31 2022;23(3). doi:10.3390/ijms23031665. DOI: https://doi.org/10.3390/ijms23031665
Lluch A, Barrios CH, Torrecillas L, et al. Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01). J Clin Oncol. Jan 20 2020;38(3):203-213. doi:10.1200/JCO.19.00904. DOI: https://doi.org/10.1200/JCO.19.00904
Mayer IA, Zhao F, Arteaga CL, et al. Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. J Clin Oncol. Aug 10 2021;39(23):2539-2551. doi:10.1200/JCO.21.00976. DOI: https://doi.org/10.1200/JCO.21.00976
Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med. Jun 24 2021;384(25):2394-2405. doi:10.1056/NEJMoa2105215. DOI: https://doi.org/10.1056/NEJMoa2105215
Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. Feb 27 2020;382(9):810-821. doi:10.1056/NEJMoa1901917. DOI: https://doi.org/10.1056/NEJMoa1910549
Ignatiadis M, Bailey A, McArthur H, et al. Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical Trial. Jama. Jan 30 2025;333(13):1150-1160. doi:10.1001/jama.2024.26886. DOI: https://doi.org/10.1001/jama.2024.26886
Nader-Marta G, Monteforte M, Agostinetto E, et al. Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis. ESMO Open. Mar 2024;9(3):102390. doi:10.1016/j.esmoop.2024.102390. DOI: https://doi.org/10.1016/j.esmoop.2024.102390
Zhang D, Jahanfar S, Rabinowitz JB, et al. Role of circulating tumor DNA in early-stage triple-negative breast cancer: a systematic review and meta-analysis. Breast Cancer Res. Mar 12 2025;27(1):38. doi: 10.1186/s13058-025-01986-y. DOI: https://doi.org/10.1186/s13058-025-01986-y
Xu J, Fang K, Li X, Han L, Sun S, Sun T. From residual risk to precision intervention: the evolving role of minimal residual disease in breast cancer management. Cancer Biol Med. Nov 28 2025;22(12):1493-1514. doi: 10.20892/j.issn.2095-3941.2025.0431. DOI: https://doi.org/10.20892/j.issn.2095-3941.2025.0431
Authors
Copyright (c) 2026 Archives of Breast Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright©. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License, which permits copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, except for commercial purposes.